Skip to main content

Advertisement

SpringerLink
Log in

Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

It has been shown that breast cancer patients with N3a (10 positive lymph nodes) had a poor prognosis. We planned to investigate the clinical outcome BC patients who presented with N3a disease and had no evidence of systemic metastasis at the time of diagnosis. We made a retrospective chart review of breast cancer patients who had ≥10 positive lymph nodes and received adjuvant systemic therapy in Marmara University Hospital between 1998 and 2008. We recorded clinical, pathologic and treatment characteristics of the patients and analyzed the survival outcome. We identified 73 patients with N3a disease who were treated in Marmara University Hospital between 1998 and 2008. The median age was 52. Most (75%) of the patients had invasive ductal histology, 75% had T2/T3 tumors, 36% had grade 3 tumors. The median number of metastatic lymph nodes was 15. Estrogen and progesterone receptors were both positive in 61% and both negative in 16+ tumors. Her-2/neu status was assessed in 68% of the tumors; 18% of patients had 3+ and 50% had negative scores. Six patients had triple negative tumors. All patients except one received adjuvant chemotherapy and radiotherapy. Seventy-four percent of patients received anthracycline/taxane-based chemotherapy. Fifty-nine patients received adjuvant endocrine therapy, 42% them received aromatase inhibitors. Five of the 13 Her-2 positive patients received adjuvant trastuzumab. With a median follow-up of 47 months, 5-year disease and overall survival rates were 66 and 81%, respectively. Twenty-four patients had relapsed and 14 patients died. Her-2 status and the number of lymph nodes (<20 vs. ≥20) had significant impact on disease-free survival in the univariate analysis (P = 0.03 and 0.05, respectively) and Her-2 retained its significant impact on disease-free survival in the multivariate analysis (P = 0.05). The prognosis of BC patients with N3a disease has changed favorably in the past decade with the current standards of care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. van ‘t Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.

    Article  Google Scholar 

  2. van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.

    Article  PubMed  Google Scholar 

  3. Carter CL, Allen C, DE Henson. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181–7.

    Article  PubMed  CAS  Google Scholar 

  4. Nemoto T, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45(12):2917–24.

    Article  PubMed  CAS  Google Scholar 

  5. Singletary SE, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628–36.

    Article  PubMed  Google Scholar 

  6. Early Breast Cancer Trialists’ CollaborativeGroup (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.

    Article  Google Scholar 

  7. Bria E, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer. 2006;106:2337–44.

    Article  PubMed  CAS  Google Scholar 

  8. De Laurentiis M, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44–53.

    Article  PubMed  Google Scholar 

  9. Ferguson T, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007; Issue 4.

  10. Walker MS, et al. The natural history of breast cancer with more than 10 positive nodes. Am J Surg. 1995;169:575–9.

    Article  PubMed  CAS  Google Scholar 

  11. Buzdar AU, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992;69(2):448–52.

    Article  PubMed  CAS  Google Scholar 

  12. Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M, German Breast Cancer Study Group. Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer. 2001;37(9):1123–31.

    Article  PubMed  CAS  Google Scholar 

  13. Peters WP, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA–13. J Clin Oncol. 2005;23:2191.

    Article  PubMed  Google Scholar 

  14. Tallman MS, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349:17.

    Article  PubMed  CAS  Google Scholar 

  15. Zander AR, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004;22:2273.

    Article  PubMed  CAS  Google Scholar 

  16. Fumoleau P, et al. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes. J Clin Oncol. 2001;19(3):612–20.

    PubMed  CAS  Google Scholar 

  17. Eiermann W, German Adjuvant Breast Cancer Group, et al. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93)–the German Adjuvant Breast Cancer Group. Eur J Cancer. 2010;46(1):84–94.

    Article  PubMed  CAS  Google Scholar 

  18. Tsuchiya A, Kanno M, Abe R. The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodes. Surg Today. 1997;27(10):902–6.

    Article  PubMed  CAS  Google Scholar 

  19. Faneyte IF, et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res. 2004;10(13):4457–63.

    Article  PubMed  CAS  Google Scholar 

  20. Diab SG, et al. Radiation therapy, survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998;16(5):1655–60.

    PubMed  CAS  Google Scholar 

  21. Gianni AM, et al. Efficacy, toxicity, applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol. 1997;15(6):2312–21.

    PubMed  CAS  Google Scholar 

  22. Peters WP, et al. High-dose chemotherapy, autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11(6):1132–43.

    PubMed  CAS  Google Scholar 

  23. Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer, 10 or more positive axillary lymph nodes. J Clin Oncol. 1996;14(1):66–9.

    PubMed  CAS  Google Scholar 

  24. Peto R, et al., Early Breast Cancer Trialists’ Collaborative Group. The worldwide overview: new results for systemic adjuvant therapies. San Antonio breast cancer symposium. 2007. Abstr P–1.

  25. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–9.

    Article  PubMed  CAS  Google Scholar 

  26. Hudis C. CAGB 9344/CAGB C9741: what we have learnt? Eur J Cancer. 2006;Supp 4(5):10–2.

    Google Scholar 

  27. Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. HER-2 as a target for breast cancer therapy. Clin Cancer Res. 2009;15(6):1848–52.

    Article  PubMed  CAS  Google Scholar 

  28. Jabro G, et al. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or =10 positive axillary nodes. Int J Radiat Oncol Biol Phys. 1999;44(2):273–80.

    Article  PubMed  CAS  Google Scholar 

  29. Dowsett M, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.

    Article  PubMed  CAS  Google Scholar 

  30. Sørlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–74.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Marmara University Hospital, Istanbul, Turkey

    Gul Basaran, Cabuk Devrim, Hale B. Caglar, Bahadır Gulluoglu, Handan Kaya, Selcuk Seber, Taner Korkmaz, Ferhat Telli, Muharrem Kocak, Faysal Dane, Fulden P. Yumuk & Serdar N. Turhal

Authors
  1. Gul Basaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cabuk Devrim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hale B. Caglar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bahadır Gulluoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Handan Kaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Selcuk Seber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Taner Korkmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ferhat Telli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Muharrem Kocak
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Faysal Dane
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Fulden P. Yumuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Serdar N. Turhal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gul Basaran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basaran, G., Devrim, C., Caglar, H.B. et al. Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?. Med Oncol 28, 726–732 (2011). https://doi.org/10.1007/s12032-010-9516-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9516-1

Keywords

Search

Navigation